Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (IZSEZ0_193593)
Received: 26 January 2021
Accepted: 3 May 2021
First Online: 11 October 2021
: The BBDPS was approved by the Independent Ethics Committee “Parc de Salut Mar”, Barcelona, and registered at Clinicaltrials.gov (Identifier: NCT03847038). All participating subjects and signed the study’s informed consent form that had also been approved by the Independent Ethics Committee “Parc de Salut Mar”, Barcelona.
: Not applicable.
: GBF reports grants from Alzheimer Forum Suisse, Académie Suisse des Sciences Médicales, Avid Radiopharmaceuticals, Biogen, GE International, Guerbert, Association Suisse pour la Recherche sur l’Alzheimer, IXICO, Merz Pharma, Nestlé, Novartis, Piramal, Roche, Siemens, Teva Pharmaceutical Industries, Vifor Pharma, and Alzheimer’s Association; he has received personal fees from AstraZeneca, Avid Radiopharmaceuticals, Elan Pharmaceuticals, GE International, Lundbeck, Pfizer, and TauRx Therapeutics.PS has received consultancy fees (paid to the institution) from AC Immune, Alkermes, Alnylam, Anavex, Biogen, Brainstorm Cell, Cortexyme, Denali, EIP, ImmunoBrain Checkpoint, GemVax, Genentech, Green Valley, Novartis, Novo Noridisk, PeopleBio, Renew LLC, Roche. He is PI of studies with AC Immune, CogRx, FUJI-film/Toyama, IONIS, UCB, Vivoryon. He serves on the board of the Brain Research Center.WF has received consultancy fees (paid to the institution) from Oxford Health Policy Forum CIC, Roche BV. She has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, and WebMD Neurology (Medscape). She has performed contract research for Biogen MA Inc and Boehringer Ingelheim. All funding is paid to her institution. WF is associate editor at Alzheimer’s, Research & Therapy.JLM is currently a full-time employee of Lundbeck and has previously served as a consultant or at advisory boards for the following for-profit companies, or has given lectures in symposia sponsored by the following for-profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, ProMIS Neurosciences.The other co-authors declare that they have no competing interests.